Pressure BioSciences (PBIO) Reports Q2 Loss of $0.72
More News related to PBIO
- Video Interview: Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.
- Pressure BioSciences, Inc. (PBIO) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
- Pressure Biosciences, Inc. Announces the Release of Its Much Anticipated, Next Generation Sample Preparation Product: the PCT MicroTube Adapter Kit
- Pressure BioSciences, Inc. to Discuss First Quarter 2009 Financial Results and Provide Business Update
- Pressure BioSciences (PBIO) Reports a Q3 Loss, Comments on Outlook
Pressure BioSciences (Nasdaq: PBIO) reports a Q2 loss of $0.72, versus the analyst estimate of ($0.64). Revenues for the quarter were $120.2K, versus the consensus of $160K.
Pressure BioSciences, Inc., a life sciences company, engages in the research, development, and commercialization of pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.
Related Categories
EarningsStocks Mentioned
-0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
